Market Overview - The A-share market experienced a significant rebound in the afternoon of March 18, with the Shanghai Composite Index rising by 0.32%, the Shenzhen Component Index increasing by 1.05%, and the ChiNext Index gaining 2.02% [4] - A total of 3,554 stocks rose, with 70 hitting the daily limit up, while 1,831 stocks declined [5] Sector Performance - The computing power industry chain saw a collective surge, particularly in the computing power leasing sector, with stocks like Meiliyun, Jialitu, and Data Port hitting the daily limit up [6] - The semiconductor industry chain also rallied, led by storage chip stocks, with companies such as Tongyou Technology, Shenkeda, and Chengbang Co. hitting the daily limit up [7] Price Adjustments and Market Drivers - Alibaba Cloud announced a price increase for its AI computing power and storage products, with increases ranging from 5% to 34% due to rising global AI demand and supply chain costs [10][12] - Baidu Cloud also announced price hikes for AI computing-related products, with increases of approximately 5% to 30% effective from April 18, 2026 [13] - NVIDIA's CEO expressed optimism about the future of AI agents and OpenClaw, suggesting it could become the next ChatGPT, which positively impacted the stock prices of AI companies like MiniMax and Zhipu [14][15] Market Sentiment - The decline in oil prices has improved market risk appetite, influenced by Iraq's agreement to resume oil exports through Turkey, bypassing the Strait of Hormuz [16]

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于成都先导药物开发股份有限公司 2026 年第一次临时股东会的法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）受成都先导药物开发 股份有限公司（以下简称"贵公司"）的委托，根据《中华人民共和国公司法》 （以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规 则》）等中国现行有效的有关法律、行政法规、部门规章、规范性文件（以下 合称"法律法规"，仅为本法律意见书法律适用之目的，不包括中国香港特别 行政区、中国澳门特别行政区及台湾地区的法律法规）及《成都先导药物开发 股份有限公司章程》（以下简称《公司章程》）的有关规定，就贵公司 2026 年 第一次临时股东会（以下简称"本次股东会"）有关事宜出具本法律意见书。 本法律意见书仅就本次股东会的召集和召开程序是否符合法律、行政法规 和《公司章程》的规定，以及出席本次股东会人员的资格、本次 ...

证券代码：688222 证券简称：成都先导 公告编号：2026-008 成都先导药物开发股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 3 月 2 日 （二） 股东会召开的地点：成都市双流区慧谷东一路 8 号天府国际生物城 C2 栋成都先导药物开发股份有限公司二楼大会议室 | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例 | 票数 | 比例 | 票数 | 比例 | | | | （%） | | （%） | | （%） | | 普通股 | 125,400,067 | 92.8091 | 9,706,531 | 7.1838 | 9,517 | 0.0070 | （二） 关于议案表决的有关情况说明 议案 1 为普通决议事项，已经出席本次股东会的股东（包 ...

Financial Performance Summary - In 2025, the company achieved operating revenue of 525.57 million RMB, representing a year-on-year increase of 23.09% [2] - The net profit attributable to the parent company was 114.02 million RMB, showing a significant year-on-year growth of 122.01% [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 116.59 million RMB, with a year-on-year increase of 102.99% [2] - Total assets at the end of the reporting period reached 1,955.93 million RMB, up 11.35% year-on-year [2] - The equity attributable to the parent company was 1,492.15 million RMB, reflecting a year-on-year growth of 7.11% [2] Business Operations and Key Factors - The company's core business segment, DEL, maintained steady growth, contributing to overall profit enhancement due to high gross margins [3] - The UK subsidiary further solidified the development of the FBDD/SBDD platform, with milestone revenues achieved from client projects [3] - The OBT segment showed significant revenue growth through the commercialization of small nucleic acid projects, aided by the efficient operation of an automated high-throughput chemical synthesis platform [3] - The company reported a significant increase in operating profit of 125.67 million RMB, a year-on-year growth of 99.58% [5] - The total profit reached 125.91 million RMB, marking a year-on-year increase of 100.62% [5] Non-Operating Gains and Losses - The company experienced a decrease in fair value losses on financial liabilities, which positively impacted overall financial performance [4]

Core Viewpoint - Chengdu Xian Dao (688222.SH) reported a significant increase in both revenue and net profit for the fiscal year 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company achieved an operating revenue of 526 million yuan, representing a year-on-year growth of 23.09% [1] - The net profit attributable to the shareholders of the parent company reached 114 million yuan, marking a substantial year-on-year increase of 122.01% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 117 million yuan, reflecting a year-on-year growth of 102.99% [1]

Group 1 - The core viewpoint of the article is that Chengdu XianDao announced significant financial growth for the year 2025, with a projected total revenue of 525.57 million yuan, representing a year-on-year increase of 23.09% [2] - The net profit attributable to the parent company is expected to reach 114.02 million yuan, showing a substantial year-on-year growth of 122.01% [2]

Financial Performance - The total operating revenue for 2025 reached RMB 525.57 million, representing a year-on-year increase of 23.09%[2] - The net profit attributable to the parent company was RMB 114.02 million, showing a significant year-on-year growth of 122.01%[4] - The basic earnings per share increased to RMB 0.28, reflecting a growth of 115.38% compared to the previous year[3] - The total assets at the end of the reporting period amounted to RMB 1,955.93 million, up 11.35% year-on-year[4] - The company's operating profit was RMB 125.67 million, which is a 99.58% increase from the previous year[8] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 116.59 million, marking a 102.99% increase year-on-year[4] Business Segments - The core business segment, DEL, maintained steady growth and contributed to overall profit improvement[6] - The OBT segment showed significant revenue growth due to successful commercialization of small nucleic acid projects[6] Financial Stability - The company reported a decrease in fair value losses on financial liabilities, positively impacting overall financial performance[10] - There are no significant uncertainties affecting the accuracy of the performance report as of the announcement date[11]

Group 1 - The China Securities 2000 ETF (563300) opened down 0.64% at 1.545 yuan on February 27 [1] - Major holdings in the ETF include Ding Tong Technology down 3.14%, Jiao Cheng Ultrasonic down 2.83%, and Pingtan Development down 2.08% [1] - The ETF's performance benchmark is the China Securities 2000 Index return, managed by Huatai-PB Fund Management Co., with a return of 55.21% since its establishment on September 6, 2023, and a 2.28% return over the past month [1]

本报告依据中国资产评估准则编制 成都先导药物开发股份有限公司拟增资所涉及的 成都先衍生物技术有限公司 股东全部权益价值 资产评估报告 中天华资评报字[2026]第10249号 (共1册, 第1册) 北京中 间责任公司 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020122202600199 | | | --- | --- | --- | | 合同编号: | 中天华合同字[2026]第P0251号 | | | 报告类型: | 法定评估业务资产评估报告 | | | 报告文号: | 中天华资评报字[2026]第10249号 | | | 报告名称: | 成都先导药物开发股份有限公司拟增资所涉及的成都先衍生物技 术有限公司股东全部权益价值资产评估报告 | | | 评估结论: | 453,960,000.00元 | | | 评估报告日: | 2026年02月26日 | | | 评估机构名称: | 北京中天华资产评估有限责任公司 | | | 签名人员: | 彭跃龙 (资产评估师) 正式会员 编号: 1120068 | | | | 郝伟涛 见习会员 编号:11240048 | (资产评估师) | ...

二〇二六年三月 1 成都先导药物开发股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 2026 年第一次临时股东会会议资料 为维护全体股东的合法利益，确保股东会的正常秩序和议事效率，保证大会 的顺利进行，成都先导药物开发股份有限公司（以下简称"公司"或"成都先导"）根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《成都先导药物开发股份有限公司章程》（以下 简称"《公司章程》"）及《成都先导药物开发股份有限公司股东会议事规则》（以 下简称"《股东会议事规则》"）及相关规定，特制定本须知。 一、为确认出席大会的股东或代理人或其他出席者的出席资格，会议工作人 员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签 到手续，并请按规定出示身份证明文件或法定代表人/执行事务合伙人委派代表身 份证明书、授权委托书等相关文件，经验证后方可出席会议，公司有权拒绝不符 合条件的人士进入会场。会议开始后，由会议 ...